Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0497/02 (Insulinotropic hormone/GENERAL HOSPITAL) 27-05-2004
Facebook X Linkedin Email

T 0497/02 (Insulinotropic hormone/GENERAL HOSPITAL) 27-05-2004

European Case Law Identifier
ECLI:EP:BA:2004:T049702.20040527
Date of decision
27 May 2004
Case number
T 0497/02
Petition for review of
-
Application number
93203087.7
IPC class
C07K 7/10
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 38.28 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Insulinotropic hormone

Applicant name
THE GENERAL HOSPITAL CORPORATION
Opponent name
-
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 83 1973
Rules of procedure of the Boards of Appeal Art 10
Guidelines_, 2001 C.IV.4.7; C.IV.4.12
Keywords
Sufficiency of disclosure (no)
Catchword
-
Cited decisions
T 0222/00
Citing decisions
T 1309/08

I. The appeal was lodged by the Applicants (Appellants) against the decision of the Examining Division to refuse under Article 97(1) EPC the patent application EP 93 203 087.7, publication number EP 0 587 255 having the title: "Insulinotropic hormone". The application is a divisional application of the earlier application with the publication number EP 0 305 387 in accordance with Article 76 EPC.

II. Appellant's request (Annex C to the decision under appeal) in relation to which the Examining Division decided the substantive issues consisted of claims 1 and 2 which read:

"1. The use of a peptide having insulinotropic activity substantially similar to GLP-1 (7-37) in the preparation of an agent for the treatment of diabetes mellitus, wherein the peptide consists of the GLP-1(7- 37) sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys- Gly-Arg-Gly

but where the sequence lacks one amino acid.

2. The use as claimed in claim 1, wherein the peptide has the formula:

(1) H2N - X - CO - R1

wherein R1 represents OH, OM, or NR2R3; where M is a pharmaceutically acceptable cation or a C1-C6 branched or unbranched alkyl group; each of R2 and R3 are the same or different and independently represent a hydrogen atom or a C1-C6 branched or unbranched alkyl group; and X is a peptide according to claim 1; or an acid salt thereof."

III. The Examining Division decided at oral proceedings not to allow into the proceedings under Rule 86(3) EPC two requests filed by the Appellants on 21 September 2001, as they both contained a claim 3 which was not based on the application as filed, contrary to the requirements of Article 123(2) EPC. Claim 3 read:

"3. The use as claimed in claim 1 or claim 2, wherein the agent is for the treatment of maturity onset diabetes mellitus."

IV. It view of this refusal the Applicants agreed to continue at the oral proceedings before the Examining Division on the basis of a previous request consisting of claims 1 and 2 shown in section (II) above.

The Examining Division decided that the application did not disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art, contrary to the requirements of Article 83 EPC. The technical effect expressed in the claims, namely the usefulness of a peptide consisting of, or comprising the sequence of amino acids 7 to 37 of glucagon-like peptide I (GLP-1(7-37)) lacking one amino acid, for the preparation of an agent for the treatment of diabetes mellitus, had not been disclosed in the application.

Moreover, the decision under appeal contains a remark on page 3, saying that the Examining Division "...is also of the opinion that the involvement of an inventive step cannot be recognised...".

V. The Appellants had requested in writing that the decision under appeal be set aside and that a patent be granted on the basis of one of the requests identified in the Grounds of Appeal filed on 19 March 2002.

VI. The Board expressed its preliminary opinion in a communication dated 28 October 2003, which was annexed to the summons to attend oral proceedings on 27 May 2004.

VII. On 26 March 2004 the Appellants filed a new main request and five auxiliary requests on which a patent should be granted. The requests read as follows:

Main request:

"1. Use of a peptide in the preparation of an agent for the treatment of diabetes mellitus, wherein the peptide either

(i) consists of the GLP-1(7-37) sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys- Gly-Arg-Gly; or

(ii) or a functional derivative of the GLP-1 (7-37) peptide which has insulinotropic activity substantially similar to GLP-1 (7-37) and consists of the GLP-1 (7- 37) sequence set out above but where the sequence lacks one amino acid.

2. Use of a peptide having insulinotropic activity substantially similar to GLP-1 (7-37) in the preparation of an agent for the treatment of diabetes mellitus, wherein the peptide has the formula:

(1) H2N - X - CO - R1

wherein R1 represents OH, OM, or NR2R3; where M is a pharmaceutically acceptable cation or a C1-C6 branched or unbranched alkyl group; each of R2 and R3 are the same or different and independently represent a hydrogen atom or a C1-C6 branched or unbranched alkyl group; and X consists either of the GLP-1 (7-37) sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys- Gly-Arg-Gly; or a functional derivative of GLP-1 (7-37) sequence set out above where the sequence lacks one amino acid; or an acid addition salt thereof.

3. Use as claimed in claim 1 or claim 2, wherein the agent is for the treatment of maturity onset diabetes mellitus."

First auxiliary request:

"1. Use of a peptide having insulinotropic activity substantially similar to GLP-1 (7-37) in the preparation of an agent for the treatment of diabetes mellitus, wherein the peptide consists of the GLP-1(7- 37) sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys- Gly-Arg-Gly

but where that sequence lacks one amino acid.

2. Use of a peptide having insulinotropic activity substantially similar to GLP-1 (7-37) in the preparation of an agent for the treatment of diabetes mellitus, wherein the peptide has the formula:

(1) H2N - X - CO - R1

wherein R1 represents OH, OM, or NR2R3; where M is a pharmaceutically acceptable cation or a C1-C6 branched or unbranched alkyl group; each of R2 and R3 are the same or different and independently represent a hydrogen atom or a C1-C6 branched or unbranched alkyl group; and X consists either of the GLP-1 (7-37) sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys- Gly-Arg-Gly but where the sequence lacks one amino acid or an acid addition salt thereof."

Claim 3 was identical to claim 3 of the main request.

Second auxiliary request:

Claims 1 and 3 were identical to claims 1 and 3 of the first auxiliary request.

"2. Use of a peptide having insulinotropic activity substantially similar to GLP-1 (7-37) in the preparation of an agent for the treatment of diabetes mellitus, wherein the peptide has the formula:

(1) H2N - X - CO - R1

wherein R1 represents NR2R3; where R2 and R3 are the same and represent a hydrogen atom and X is a peptide according to claim 1; or an acid addition salt thereof."

Third auxiliary request:

"Consists of the claims of the Main, first or second auxiliary requests amended to delete the wording "substantially similar to GLP-1(7-37)" in Claims 1 or 2."

Fourth auxiliary request:

"Consists of the Claims of the Main, first, second or third auxiliary requests with Claim 3 deleted."

Fifth auxiliary request:

"Consists of the claims of the Main, first, second, third or fourth auxiliary requests with Claim 1 or 2 deleted."

VIII. The following comments were provided by the Appellants on pages 3 to 4 of their letter with regard to these requests:

"You will see that the third auxiliary request consists of the simple deletion of a phrase from the earlier requests. Also, the fourth and fifth auxiliary request consist of the simple deletion of a claim.

We believe that the above presentation of the third to fifth auxiliary requests is clear and is the best way of avoiding a proliferation of auxiliary requests. However, if the Board would prefer us to file separate sets of claims for each of the auxiliary requests, we would be happy to do so. Unless the Board contacts us to the contrary, we assume that it is happy with our presentation of auxiliary requests.

If the Board considers that there is any other patentable subject-matter, we request that we be allowed to submit a further auxiliary request to that subject-matter."

IX. Two days before the scheduled date the Board were informed that the Appellants would not attend oral proceedings.

X. Oral proceedings were held on 27 May 2004 in the absence of the Appellants pursuant to Rule 71(2) EPC.

XI. The submissions of the Appellants, as far as they are relevant for the present decision, may be summarised as follows:

The statement in the appealed decision relating to lack of inventive step should be disregarded by the Board, as it was added by the Examining Division after the oral proceedings. The refusal to allow into the proceedings the Appellant's requests of 21 September 2001 at the oral proceedings under Rule 86(3) EPC amounted to a procedural violation. Appellant's right to be heard had been violated (Article 113(1) EPC), because the Examining Division did not send a communication first, giving the reasons for refusing the requests pursuant to the then applicable Guidelines for Examination in the EPO, part C, chapter VI, point 4.12.

The requirements of Article 83 EPC were met by the present application. There were only 31 possible members in the group of GLP-1(7-37) peptides lacking one amino acid and the application taught on pages 6 and 7 how to produce them. No undue experimentation would have been required to assay the insulinotropic properties of these 31 peptides, as the relevant assay methods were disclosed in the present application. Moreover, testing the 31 compounds involved, for determining their effectiveness in treating diabetes, by using methods well known in the art, would not represent undue burden.

Several post published documents have confirmed that GLP-1(7-36) had the same biological effects and the same activity as GLP-1(7-37).

It would be most unfair for the Board to refuse the application on the basis that no supporting evidence had been filed, as there had been no clear indication in the earlier proceedings that in the absence of such evidence a negative decision might be taken. Such procedure would violate Appellant's right to be heard according to Article 113(1) EPC.

Procedural matter

1. The appeal meets the requirements of Articles 106 to 108 EPC and Rule 64 EPC and is thus admissible.

2. For the purpose of these appeal proceedings, the Appellant's complaint in connection with the refusal of the Examining Division to allow into the proceedings the claim requests filed on 21 September 2001, only becomes relevant in accordance with Article 10 of the Rules of Procedure of the Boards of Appeal (RPBA) if fundamental deficiencies are apparent in the first instance proceedings which require that the Board should remit the case to the first instance without considering the substantive issues. Such a fundamental deficiency would be a procedural violation of such gravity that it vitiates the basis on which Examination Division made its decision, making it necessary for the first instance to decide anew after a properly conducted procedure.

3. Two matters require consideration as to whether they amount to such a fundamental deficiency, firstly the exercise of the Examining Division of its discretion under Rule 86(3) EPC, and secondly the Appellant being informed of the reasons for the exercise of this discretion only at the oral proceedings before the Examining Division and not earlier or in writing.

4. That the new dependent claim 3 sought to be introduced into the proceedings by these belated requests was considered not to be in conformity with Article 123(2) EPC is considered by the Board an adequate and reasonable justification for the Examining Division to exercise its discretion under Rule 86(3) EPC not to allow these new claim requests into the proceedings. The Board can see no procedural violation arising from the refusal itself, let alone any fundamental deficiency.

5. The Appellant, relying on the then applicable Guidelines for Examination in the European Patent Office Part C Chapter VI point 4.12, has complained that he was sent no written communication prior to the oral proceedings giving the reasons for the refusal under Rule 86(3) EPC, nor any prior telephone indication, and that this amounted to a violation of his rights under Article 113(1) EPC. The then applicable point 4.12 read:

'If a request for amendment is to be refused under Rule 86(3), the applicant must first in compliance with Art. 113(1) be sent a communication giving the reasons for refusing the amendment. In the case of a situation as described in VI, 4.10 the applicant should be invited at the same time to request grant of the patent on the basis of the preceding acceptable version of the documents. If the applicant maintains his request for the amendment, the application must be refused under Article 97(1) since, in these circumstances, there is no text of the application which has been agreed by the applicant and allowed by the Examining Division (Article 113(2)).'

6. This has to be read in the context of the purpose of Rule 86(3) EPC, which was to give the Examination Division a discretion to refuse amendments to the claims not made in answer to the first communication, so as to ensure that the examination procedure is brought to a conclusion in as few actions as possible (Cf. then applicable Guidelines Part C Chapter VI point 4.7). From this and the text of point 4.12, the Board sees the purpose of the then applicable Guidelines as being to give an applicant an opportunity to avoid the situation of having a negative decision merely on the ground of there being no text agreed to by the applicant. Point 4.12 is not seen as applicable to a situation where oral proceedings take place, as the requirements of Article 113(1) EPC can then be met, as was done in the present case, by the applicant being informed of the objection at the oral proceedings and being afforded the opportunity to revert to a request submitted earlier which had been allowed into the proceedings.

7. Article 113(1) EPC merely requires applicants to be afforded the opportunity to present their comments on the grounds on which the European Patent Office bases its decision: the Article does not require a written communication nor does it specify how much time applicants should be afforded to consider and present their comments. An applicant cannot expect to amend his claim request(s) a bare month before the date set for oral proceedings, and still before the oral proceedings be sent a written communication or given a telephone notification indicating that the Examining Division proposes to exercise its discretion under Rule 86(3) EPC against the admission of the new request(s), and the reasons for this. The applicant must expect to have to deal with any problems with such late requests at the oral proceedings.

8. In conclusion, the Board sees no procedural violations as having occurred in this case, and no need or basis for remitting the case to the Examining Division pursuant to Article 10 RPBA.

9. The Board will confine itself to considering whether the reason for refusal under Article 83 EPC by the Examination Division of the request before it was correct, and also applies to the requests now pending before the Board. The Board sees other issues under Rule 86(3) EPC, and Articles 84 and 123(2) EPC, but since the Appellants instructed their representatives not to be present at the oral proceedings before the Board they have not been raised or commented on by the appellants, and cannot form a basis for the Board's decision.

10. The Board sees the reason for refusal and core objection of insufficiency by the Examining Division as being in that the claimed subject matter of use of a peptide corresponding to the amino acid sequence of GLP-1(7-37) lacking one amino acid for the preparation of an agent for a treatment of diabetes mellitus is not disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art, contrary to the requirements of Article 83 EPC, because on the information in the application plus common general knowledge the skilled person would not know which, if any at all, of the thirty odd peptides would fulfil this function. It would thus be undue burden, contrary to the requirement of sufficiently clear and complete disclosure, for a skilled person to research the claimed area for himself to find out if anything worked.

11. Independent claims 1 and 2 of the new main request now put forward cover this same subject matter, as well as additional subject matter namely the use of the full GLP-1(7-37) peptide itself, which is described as functional in the application as filed and which was not objected to by the Examining Division as it was not part of the subject matter of the claims before the first instance. However the Board does not see that broadening the subject matter of a claim to also cover a specific use that is sufficiently described, avoids the objection of insufficiency as to the remaining subject matter of the claim if this objection is valid as to this remaining subject matter by itself. Nor does the slightly modified wording compared to the claims considered by the Examining Division do anything to avoid the core objection on insufficiency in relation to the independent claims 1 and 2 of the main request.

12. Claims 1 and 2 of each of the first and second auxiliary requests are directed only to use of a peptide corresponding to the amino acid sequence of GLP-1(7-37) lacking one amino acid for the preparation of a treatment of diabetes mellitus, and again the Board considers that the slight verbal differences compared to the claims considered by the Examining Division contribute nothing to avoiding the core objection of insufficiency.

13. While the Board considers the way of presenting the various further auxiliary requests to be quite unacceptable, it appears clear that each auxiliary request will still contain at least one claim open the same core objection of insufficiency on the basis of which the first instance refused the application.

14. Thus if the Board considers the core objection of insufficiency to apply, none of the requests now put forward is allowable.

15. On page 3, lines 10 to 23, in the summary of the invention, the application discloses that GLP-1(7-37), "the insulinotropic hormone", is useful in the study of the pathogenesis of maturity onset diabetes mellitus and in the therapy for this disease. Page 4, lines 37 to 41 states that the invention pertains to polypeptides which are functionally similar to GLP-1(7-37), but whose sequence may contain or lack one or more amino acids compared to the naturally occurring sequence.

16. Neither the description nor the specific examples 1 to 7 disclose that a peptide falling under the definition of 'GLP- 1(7-37) lacking one amino acid' has been tested for its ability to be used for the preparation of an agent for the treatment of diabetes mellitus.

Appellants line of argumentation, namely that the invention is sufficiently disclosed because a skilled person can produce the 31 peptides falling under this definition and test them for the claimed effect is not conclusive. What is undue burden must be decided on a case by case basis.

17. The patent application does not contain any evidence that even a single one of these 31 peptides in fact shows the required biological activity. The skilled person, when trying to carry out the claimed invention, has to isolate, synthesize or produce by recombinant DNA technology said 31 peptides, and to perform tests and assays to determine whether they possess the required biological activity. This considerable research program imposed on the skilled person has to be performed with no certainty of even a single success. That any amino acid can be omitted seems impossible, so that the expectation must be that most, if not all of the minus-one GLP-1(7-37) peptides will not work.

18. The Board would like to emphasize that the biological activity of proteins is highly dependent on their secondary and tertiary structures, resulting from their primary structure, their amino acid sequence. It is common general knowledge that the deletion of a single amino acid may have great influence on the three-dimensional folding of peptides or parts thereof. There is no basis in the application to conclude that any of the 31 peptides involved, or, if any, how many thereof will show secondary and tertiary structures, giving them properties that make them candidates for use in the treatment of diabetes mellitus. In this situation, the Board can only conclude that the invention is insufficiently disclosed.

19. The Appellants further argued that several post published documents have confirmed that the activity of GLP-1(7-36) is the same as that of GLP-1(7-37).

If a disclosure is insufficient in that it provides no guidance for performing the invention, a reference to later documents showing how such performance was accomplished at a later date is incapable of curing the insufficiency (cf T 222/00 15 January 2003).

20. It is up to the Appellants to file evidence in support of their case. The decision under appeal, which decided that the present application does not meet the requirements of Article 83 EPC, was dispatched in November 2001. The Board considers that the Appellants have had ample time to provide evidence supporting their line of argumentation. Therefore, the Board does not agree with the Appellants, that it would be unfair to refuse the application without giving them an opportunity to file further evidence.

21. The Board comes to the decision that the present patent application does not disclose the claimed invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art, contrary to the requirements of Article 83 EPC.

Order

ORDER

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility